Sponsor
Akesobio
Clinical research sponsor
How to interpret these research links
Connected source recordsThe exact organization name Akesobio appears in 5 distinct published trial records. The links retain registry-reported sponsor and collaborator roles; differently spelled legal entities are not automatically merged. Recruiting status describes the current published registry snapshot, not an independently verified availability guarantee.
Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.
Advertisement
Clinical trials
5 shownA Study of Chidamide Combined With Ivonescimab in the Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) With Acquired Resistance to Immunotherapy and High Yes-associated Protein (YAP) ExpressionNCT07412262 · collaborator · 2026-08-28
RECRUITINGA Study of YL201 and Ivonescimab (AK112) in Advanced Solid TumorsNCT07208773 · collaborator · 2025-10-29
RECRUITINGPaclitaxel Polymeric Micelles Plus Ivonescimab in Recurrent or Refractory SCLCNCT07819591 · collaborator · 2026-10-01
NOT_YET_RECRUITINGA Multicenter, Single-arm Phase II Study to Evaluate the Efficacy and Safety of Fulzerasib (IBI351) in Combination With Ivonescimab (AK-112) in First-line Treatment of Advanced or Metastatic Non-small Cell Lung Cancer Patients With KRAS G12C MutationNCT06936644 · collaborator · 2025-04-30
NOT_YET_RECRUITINGStudy of Cadonilimab Combined With Chemotherapy in Recurrent / Refractory Pleural MesotheliomaNCT06416930 · collaborator · 2024-06-20
NOT_YET_RECRUITINGSponsor roles
collaborator5
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.